Ondine Biomedical (AIM:OBI), the global leader in light-activated antimicrobial therapies, reported a 39.5% reduction in ICU pneumonia in a pilot study and said the findings have been accepted for oral and poster presentation at the Canadian Critical Care Nursing Conference.
The SMURF Feasibility Pilot Study, published in Critical Care on 14 April and led by Dr Stephen Reynolds and Dr Elizabeth Rohrs at AIM Royal Columbian Hospital Foundation, represents the world's first deployment of nasal photodisinfection within an ICU and demonstrated a statistically significant reduction in early cumulative nasal pathogen burden (p < 0.01).
"The selection of the Steriwave study for oral presentation underscores the conference's commitment to spotlighting disruptive technologies that address the growing challenge of antimicrobial resistance in the ICU," Carolyn Cross, CEO of Ondine Biomedical, said.
Top-line results showed pneumonia rates fell 39.5%, from 14.9 to 9.0 cases per 1,000 ICU patient-days.
The study reported no intervention-related adverse events.
Ondine said its Steriwave nasal photodisinfection is a five-minute, non-antibiotic therapy previously shown to reduce surgical site infections in Canadian and UK hospitals.
The CACCN conference will be held 29-30 September at the Delta Prince Edward in Charlottetown, Prince Edward Island, where the abstract will be presented.
